In short
Clinical trials are studying ALXN1920 in people with primary membranous nephropathy (PMN). The main goal is to see whether ALXN1920 works better than placebo and to measure outcomes such as proteinuria, which is protein in the urine. The trial is looking at participants with a higher risk of disease progression.
Key points
- Clinical trials of ALXN1920 are studying primary membranous nephropathy (PMN), a kidney disease that can cause protein loss in the urine. The main trial listed is a Phase 2 study in 30 participants who have PMN and are at high risk for disease progression. It compares ALXN1920 with placebo. The main endpoint is the change in proteinuria measured by 24-hour UPCR. This means researchers want to see whether the treatment changes the amount of protein in the urine over time.
Trial overview
The available trial is a Phase 2 interventional study of ALXN1920 in people with primary membranous nephropathy (PMN). It is designed to compare ALXN1920 with placebo in a small group of participants.
The study aims to evaluate whether ALXN1920 can improve proteinuria, which means protein loss in the urine, in participants who are at high risk for disease progression.
Who is being studied
The target population is people with PMN who are considered at high risk for the disease getting worse. This focus matters because PMN can affect kidney function, and higher-risk patients may need closer study.
The trial plans to enroll 30 participants. That is a small study size, which is common in early mid-stage clinical research.
Trial design and phase
This is an interventional study, which means researchers assign a treatment and then measure the results. In this trial, participants receive either ALXN1920 or placebo.
A placebo is a comparison product that does not contain the active study drug. Using placebo helps researchers see whether changes are linked to ALXN1920 rather than to chance or other factors.
The study is listed as Authorised. This means the trial has been approved to move forward.
What the trial is measuring
The main outcome is the change from baseline in proteinuria based on 24-hour UPCR. Baseline means the starting point before treatment begins.
UPCR is a urine test used to estimate how much protein is lost in the urine over 24 hours. A change in this value helps show whether the study treatment is affecting kidney-related protein loss.
The brief summary says the study is evaluating the efficacy of ALXN1920 compared with placebo. Efficacy means how well a treatment works under study conditions.
What the study status means
The trial status is Authorised. This suggests the study is ready or allowed to proceed, but the data provided do not show final results.
Because only one trial is listed, the current evidence base in this dataset is limited to this single Phase 2 study in PMN.